awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30376023-DF7D7DBF-717D-403C-A0E6-A0420364787F
Q30376023-DF7D7DBF-717D-403C-A0E6-A0420364787F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30376023-DF7D7DBF-717D-403C-A0E6-A0420364787F
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me
P2860
Q30376023-DF7D7DBF-717D-403C-A0E6-A0420364787F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30376023-DF7D7DBF-717D-403C-A0E6-A0420364787F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f952e7d7dbee73fd96f7433fd922b2df4ac7233f
P2860
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada